Close Menu
    What's Hot

    Editor’s Letter – Volume 2, Issue 5, May 2026

    May 13, 2026

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Will the US Asset Intensive Life Reinsurance Market Continue Recent Growth Spurt?

      April 22, 2026

      Daiichi Life to Reinsure Whole Life Block with Prismic Life

      April 13, 2026

      Reporting Change to Provide Regulators With More Transparency into US/Offshore Asset-Intensive Life Reinsurance Treaties

      January 28, 2026

      Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

      November 26, 2025

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Life Settlement Secondary Market Returns to Growth but Plenty of Untapped Potential Still Remains

      April 22, 2026

      EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper

      March 25, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026
      Just Group

      Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

      May 11, 2026

      Bakkavor Pension Scheme Completes Bulk Purchase Annuity Buy-In With Rothesay

      May 5, 2026
      Bank of England

      Prudential Regulation Authority Publishes New Funded Reinsurance Regulations

      April 29, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

      March 25, 2026

      Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales

      March 25, 2026

      Latest CMI Model Shows Further Rise in Cohort Life Expectancy

      March 11, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026

      UK Equity Release Market Origination Slows To Begin 2026

      May 6, 2026

      CHIP Mortgage Trust Issues C$200m of Medium-Term Notes

      April 29, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026

      Editor’s Letter – Volume 2, Issue 2, February 2026

      February 11, 2026

      Editor’s Letter – Volume 2, Issue 1, January 2026

      January 14, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    An Improved Actuarial Framework for Pricing Life Settlement Litigation Risk

    Secondary Life Markets October 22, 2025By Liam Bodemeaid
    Share
    Twitter LinkedIn Email

    Nassim Nicholas Taleb – author of The Black Swan – once said “The greatest risk is not the risk you can measure. It’s the one you never saw coming.” 

    This summarises pricing litigation risk in the life settlement market quite well because that’s generally how a lot of people have priced litigation risk; they just crossed their fingers that it wouldn’t occur, or they added some percentage into the litigation risk premium, and hoped that accounted for the risk that they’ve tried to price for. 

    Litigation risk takes multiple forms, from cost of insurance increases to estate challenges, from credit risk to STOLI (stranger-owned life insurance) cases. What I’d like to introduce here is a new framework to price litigation risk with a little bit more logic, data, and structure.  

    The Traditional Life Settlement Pricing Model 

    In the traditional life settlements pricing model (Figure 1) the net present value of the benefits minus the net present value of the premiums equals the price. It often assumes fixed premiums – in the sense that whatever premium stream that is put into the net present value of premiums is not going to increase – and the benefit normally assumes that it’s a sure thing as well. 

    Figure 1: Traditional Life Settlement Pricing Model 

    Trad-Life-Pricing-Model

    It can ignore direct inclusion of litigation, cost of insurance (COI) and credit risks, and although these can be included in discount rate premia, that doesn’t always work, because the discount rate affects life settlements primarily with the life expectancy. As we will see later, these risks can increase with duration, however the discount rate premium method is a square peg into a round hole as there is sometimes also a constant risk independent of duration (e.g. STOLI). Another interesting thing about life settlements compared to other asset classes is that we have a negative coupon – we’re paying the premiums. 

    So, when you increase the discount rate on the expected premium cash flows to account for the credit risk, including COI increases, the policy price goes up. It’s working the opposite way to what would seem intuitive – that the price falls to accommodate the added risk. So, there is scope for refinement and additional sophistication to model these forms of risk that can often end up in litigation. 

    A New Life Settlement Pricing Model 

    A better way to account for these risks is as follows: 

    1. To multiply the expected benefit by one minus the default probability, which can be called the complement default probability. 
    1. Then we need to introduce another factor called the expected litigation outcomes, where we assess the net present value of the actual litigation outcomes minus the costs associated with these. And bearing in mind, these have different timeframes and litigation delays, and that all needs to be factored in. 
    1. And then on the last alteration, we adjust the expected premiums. Again, here we’re not going to assume that they’re just going to be fixed for the remainder of the term (except on guaranteed premium scenarios), and on a longer life expectancy case, on a particularly weaker carrier, that’s going to be an unrealistic assumption. So, we’re incorporating the full range of possible outcomes, that includes increases to the non-guaranteed expected premiums and multiplying these with the probabilities of increases. We also still include the scenario that they don’t increase and associate that with a probability as well, but not 100% as traditionally assumed, unless the premiums are guaranteed with a secondary shadow account or otherwise. 

    Figure 2: New model 

    This framework introduces more reliable safeguards for investors’ capital when we’re purchasing policies or valuing policies, and it beats the litigation risk premium or the credit risk premium approach that we traditionally see. 

    If we take the current PHL Variable rehabilitation as an example, there were warning signs more than a decade ago. PHL’s credit rating from AM BEST began to deteriorate in the 2014 to 2017 period before falling to BB in 2019 before having the rating completely withdrawn in 2020. This shows that we can’t just ignore credit risk or bake it into the discount rate, because it’s not appropriate to do that in all cases, especially on the weaker carriers. 

    So obviously the red flag here was the ratings erosion over time. And it can have real consequences for investors because it’s systemic across a big block of policies. We’re talking about billions of dollars here. 

    So how can we assign default probabilities into the formula? Well, one area to help is AM BEST’s Idealised Default Matrix. Here they’ve published how they see their cumulative default probability ranging with different durations and by their different ratings. 

    Figure 3: AM Best’s Idealized Default Matrix 

    AM-Best-Default-Matrix

    We can see from Figure 3 that by duration, it’s pretty low risk on BBB ratings and below. But we can see as the ratings become worse from here, the risk gets much higher. And on the longer-life expectancy cases where we’re looking at longer expected durations, we’re getting quite significant risks here. 

    So, this provides a framework for us to better predict actual cash flows and rehabilitation events going forwards. And it may mean that we need to adjust the software that we use to build in this new formula. But in my opinion, that will improve the risk management that we action in the market, and is a worthwhile development. 

    How, then, do we build in premium increases and their probabilities? Well historically COI increases have diverged significantly by carrier, with the mid-range being between 40% to 70%. And we can provide a framework for pricing these because there are various flags that we can spot to help assign the probabilities, such as AM BEST’s credit rating, as we saw with PHL. Obviously, we know that the risk was isolated to a certain block of PHL’s business but doesn’t mean that credit risk isn’t there for other carriers as well as for other blocks. 

    Some of the other red flags are known, such as the track records of certain carriers with regards to increasing their COI rates. Whilst they have freeze periods there is a risk that they increase again when those periods end. 

    And block-specific issues such as: 

    • high concentrations of older legacy, high face amount and low lapse rate policies,  
    • aggressive pricing of the premiums to capture market share, or 
    • the block being bought out by a new entity which has a new outlook on the profits.  

    All of these factors can help us to identify premium increase risks.  Each flag raises the probability of a premium hike. Again, it’s not a perfect science, but it is superior to the credit discount rate premium and the litigation discount rate premium options, and these more considered inputs provide more structure into the framework. 

    So, how might we compute the litigation cash flow vectors? Now, this is, again, not a perfect science, but with consultation with litigation firms working in the space, and AI helping to gather data, gain insights, and educate on different litigation events, we can come up with a framework to put all the different litigation scenarios together, and estimate the probabilities of these occurring, with their delays and financial outcomes. Of course, professional judgement may be needed, and all research fact checked. And from there, we can calculate the present value of all the scenarios and get a better account of the financial litigation outcome risk. 

    All of the above impacts to the price can be calculated externally if needed and equated to a discount rate premium within the traditional pricing framework, which will then allow for this framework to be used with current actuarial software. However, when stochastically projecting future cash flows, it won’t be assessing the true randomness of the portfolio outcomes, unlike this new pricing framework approach.  

    Conclusion 

    AI technology, ratings agencies, market research, and legal insights are all very useful tools that can be used to start quantifying litigation risk, the pricing of which has been ignored for too long by the life settlement market. 

    As an industry, we may need to push our software providers for extra functionality to help with this. A reminder that all of these assumptions can be independently validated for credibility by consultancy firms. By incorporating these more advanced risk factors into the industry’s pricing model, investor capital and returns will be safer, and that’s what everyone wants for the long-term security and growth of our market. 

    Liam Bodemeaid is an Actuarial Consultant at ARM (Actuarial Risk Management) 

    Any views expressed in this article are those of the author(s) and may not necessarily represent those of Longevity & Mortality Investor or its publisher, the European Life Settlement Association

    2025 - November Commentary Life Settlement Litigation Life Settlements Longevity Risk Volume 1 Issue 2 – November 2025
    Share. Twitter LinkedIn Email

    Related Posts

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026By Greg Winterton

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026By Dr. Jyotsna Kamble
    Just Group

    Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

    May 11, 2026By LMI Newsdesk

    UK Equity Release Market Origination Slows To Begin 2026

    May 6, 2026By LMI Newsdesk
    Latest Issue

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.